2024-12-24 08:45:18
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
Health/ 2023-07-22
Athos Therapeutics Receives Regulatory A...

- ATH-063 is a novel,oral,first-in-class,small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ...

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
Health/ 2023-07-22
ImmVira's oncolytic product MVR-C52...

SHENZHEN,China,March 30,2023-- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release